The Lancet. Respiratory medicine
-
Randomized Controlled Trial Multicenter Study
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
Ivacaftor has been previously assessed in patients with cystic fibrosis with Gly551Asp-CFTR or other gating mutations. We assessed ivacaftor in patients with Arg117His-CFTR, a residual function mutation. ⋯ Vertex Pharmaceuticals Incorporated.
-
Randomized Controlled Trial Multicenter Study
Permissive hypercapnia in extremely low birthweight infants (PHELBI): a randomised controlled multicentre trial.
Tolerating higher partial pressure of carbon dioxide (pCO2) in mechanically ventilated, extremely low birthweight infants might reduce ventilator-induced lung injury and bronchopulmonary dysplasia. We aimed to test the hypothesis that higher target ranges for pCO2 decrease the rate of bronchopulmonary dysplasia or death. ⋯ Deutsche Forschungsgemeinschaft.